These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 7459218)

  • 1. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
    Guo W; Zhan Y; Mery D; Siegel ER; Sun F; Cheng Y; Ashby TC; Zhang Z; Bailey C; Alapat DV; Peng H; Hadidi SA; Thanendrarajan S; Schinke C; Zangari M; van Rhee F; Tricot G; Shaughnessy JD; Zhan F
    Blood Cancer J; 2024 Feb; 14(1):30. PubMed ID: 38355688
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival rate of multiple myeloma patients in Indonesia: A retrospective study in multiple myeloma at a single institution.
    Andriandi ; Kamal AF
    Ann Med Surg (Lond); 2019 May; 41():11-15. PubMed ID: 31011418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Evolution of Prognostic Factors in Multiple Myeloma.
    Hanbali A; Hassanein M; Rasheed W; Aljurf M; Alsharif F
    Adv Hematol; 2017; 2017():4812637. PubMed ID: 28321258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant factors leading to an atypical osteonecrosis of the jaw in a patient with multiple myeloma.
    Miranda-Rius J; Brunet-Llobet L; Lahor-Soler E; Giménez-Rubio JA
    Case Rep Med; 2014; 2014():281313. PubMed ID: 25140178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib: the evidence of its clinical impact in multiple myeloma.
    Lancaster S
    Core Evid; 2006; 1(4):265-77. PubMed ID: 22496681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The albumin and monoclonal protein ratio as prognostic marker for multiple myeloma in the era of novel agents.
    Kádár K; Wolf K; Tábori J; Karádi I; Várkonyi J
    Pathol Oncol Res; 2012 Jul; 18(3):557-61. PubMed ID: 22314327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant.
    Hari PN; Zhang MJ; Roy V; Pérez WS; Bashey A; To LB; Elfenbein G; Freytes CO; Gale RP; Gibson J; Kyle RA; Lazarus HM; McCarthy PL; Milone GA; Pavlovsky S; Reece DE; Schiller G; Vela-Ojeda J; Weisdorf D; Vesole D
    Leukemia; 2009 Aug; 23(8):1528-34. PubMed ID: 19322205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving treatment strategies for myeloma.
    Morgan GJ; Davies FE
    Br J Cancer; 2005 Jan; 92(2):217-21. PubMed ID: 15655538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients.
    Sirohi B; Powles R; Mehta J; Treleaven J; Raje N; Kulkarni S; Rudin C; Bhagwati N; Horton C; Saso R; Singhal S; Parikh R
    Med Oncol; 2001; 18(1):39-50. PubMed ID: 11778969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.
    Diem H; Fateh-Moghadam A; Lamerz R
    Clin Investig; 1993 Nov; 71(11):918-23. PubMed ID: 8312685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of prognostic factors in plasmacytoma].
    Gassmann W; Haferlach T; Schmitz N; Kayser W; Euler HH; Drews J; Löffler H
    Klin Wochenschr; 1984 Oct; 62(19):896-905. PubMed ID: 6503212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
    Cuzick J; Cooper EH; MacLennan IC
    Br J Cancer; 1985 Jul; 52(1):1-6. PubMed ID: 3893505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report on the second myelomatosis trial after five years of follow-up. Medical Research Council's Working Party on Leukaemia in Adults.
    Br J Cancer; 1980 Dec; 42(6):813-22. PubMed ID: 7006663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.
    Br J Cancer; 1980 Dec; 42(6):823-30. PubMed ID: 7006664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification and prognostic variables in myelomatosis.
    Hansen OP; Galton DA
    Scand J Haematol; 1985 Jul; 35(1):10-9. PubMed ID: 3901239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic features in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.
    Br J Cancer; 1980 Dec; 42(6):831-40. PubMed ID: 7459218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival in myelomatosis. A report to the MRC working party on leukaemia in adults.
    Buckman R; Cuzick J; Galton DA
    Br J Haematol; 1982 Dec; 52(4):589-99. PubMed ID: 6958312
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.